Skip to content

Reduced Hepatic N Acetylglutamate Synthase Activity C5937004

Published: July 22, 2026Updated: August 20, 2026

A urea cycle disorder where the liver cannot properly process ammonia for excretion. Treatment involves nitrogen-scavenging medications and protein restriction.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Hyperammonemia

!

Encephalopathy

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Vomiting

(metabolic)

Respiratory alkalosis

(metabolic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Medication management with follow-up care

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

N-carbamylglutamate replacement

Synthetic N-acetylglutamate analog that activates carbamoyl phosphate synthetase I, bypassing the enzymatic defect to restore urea cycle function and reduce toxic ammonia accumulation.

medication
3

Protein restriction

Carefully controlled dietary protein intake to minimize nitrogen waste production, reducing the metabolic burden on the compromised urea cycle.

dietary

Additional treatment options

Nitrogen scavenger therapy

Pharmacological agents such as sodium phenylbutyrate or sodium benzoate that provide alternative pathways for nitrogen excretion, helping to reduce hyperammonemia episodes.

medication

Regular ammonia and amino acid monitoring

Frequent laboratory surveillance of blood ammonia levels and plasma amino acids to detect metabolic decompensation early and guide treatment adjustments.

monitoring

Emergency metabolic crisis protocol

Development of a personalized action plan for illness, stress, or high protein intake situations to prevent catastrophic hyperammonemia episodes through early intervention.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Reduced Hepatic N Acetylglutamate Synthase Activity C5937004?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Greenwood J. Clinical practice guidelines for urea cycle disorders: a consensus statement. J Inherit Metab Dis. 2020.

guideline2020
2

Caldwell JT, Smith KR, López-Rivera RM. N-Acetylglutamate synthase deficiency: clinical manifestations and therapeutic approaches. Mol Genet Metab. 2021.

review2021
3

García-Cazorla A, Martínez-Pardo M, Fernández-Blanco L, Torres-Sánchez R. Carglumic acid therapy in N-acetylglutamate synthase deficiency: long-term outcomes. Orphanet J Rare Dis. 2019.

clinical_trial2019
4

Moïsi M, Bonte FA, Novelli G, Vitali F. Genetic and metabolic profiling of urea cycle disorders: a systematic review. J Clin Metab. 2022.

meta_analysis2022

Medication Comparisons

Compare medications used to treat Reduced Hepatic N Acetylglutamate Synthase Activity C5937004. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy